Clinical trial NCT04688996: Yersinia Pestis Lateral Flow Immunoassay for Blood Samples
Official title: Point of Care Diagnostic to Identify the Causative Agent of the Plague in Blood Samples
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Plague
Plague, Bubonic
Plague, Pneumonic
Yersinia Pestis Plague
Yersinia Pestis; Bubo
Yersinia Pestis; Pneumonia
Yersinia Sepsis
Yersinia Pestis Infection
Bubo; Yersinia Pestis
Bubonic; Plague, Skin
Pneumonic Plague
Keywords: Yersinia pestis Lateral Flow Device
Lateral Flow Device
Point of Care testing, plague
Point of Need testing, plague
Plague
Yersinia pestis
Yersinia pestis antigens
Yersinia pestis LcrV antigen
Plague rapid test
Yersinia rapid test
Bubonic plague
Sputum
Bubo aspirate
Pneumonic plague
Yersinia pestis ELISA
Yersinia pestis EIA
Black plague
Black death
Yersinia LcrV protein
Yersinia F1 antigen
Yersinia PCR
Lateral Flow Immunoassays
Lead sponsor: Brimrose Technology Corporation
Sponsor class: INDUSTRY
Collaborators: name: Northern Arizona University
name: New Horizons Diagnostics Corporation
name: Institut Pasteur de Madagascar
name: Naval Health Research Center
First posted: 2020-12-30
Enrollment: 500
Sex: ALL
Minimum age (years): 5
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Malagasy Participants. Subjects will be recruited at rural health centers throughout Madagascar. Participants will be comprised of rural people with symptoms consistent with plague. The Madagascar Ministry of Public Health requires declaration of all suspected human plague cases and collection of biological samples (sputum and/or bubo aspirates) from these cases for medical workup for confirmation.

USN Health Center Participants. The subject population will consist of active duty US Naval personnel and DoD beneficiaries presenting to participating study sites in the United States with influenza-like symptoms (fever, cough, sore throat). Since the US is non-endemic for plague, all participants will be presumed to be negative for Y. pestis.

Brief summary: Plague is a deadly but highly treatable disease caused by the bacterium Y. pestis. Due to the historical development of Y. pestis as a bioweapon by several nation states, it is listed by the US as a potential bioweapon that could be used against US warfighters. Although this bacterium is ecologically established worldwide, it mostly affects impoverished people who live in rural low-resource areas of Madagascar. Plague is acquired directly from bites of infected fleas but, if left untreated, it can progress to the highly lethal pneumonic form that can result in human to human transmission. With the dangers of pneumonic plague in the context of both natural outbreak and as a bioweapon used against warfighter, the goal of this study is to investigate a diagnostic test that is able to rapidly and locally diagnose this disease in low-resource settings. This study aims to evaluate a US-developed new LFI (Lateral Flow Immunoassay) assay intended for capillary blood (finger-prick) to diagnose humans infected with Y. pestis. The investigators will rigorously validate with assay on human populations from active plague sites and correlate the results with the results of paired clinical samples used in standard medical workup using existing diagnostics tests.

Detailed description: The purpose of this study will be to generate the data required to thoroughly validate the ability of plague LFI assay (Lateral Flow Immunoassay) to accurately diagnose human infections with Y. pestis. These validation data will eventually be presented to US Food and Drug Administration (FDA; along with data from other studies that NAU will not participate) to seek approval for commercial license. The objective will be to validate this assay on the capillary blood of humans suspected to have plague as well as a study cohort likely to not have plague. From the suspected population; the specific aims of this study are to enroll up to 300 participants who present clinical signs of illness based on specific inclusion criteria. We will collect two types of blood samples from enrolled participants 1) capillary blood from a finger prick and 2) venous blood. The capillary blood will be used for direct testing on the LFI assay and the venous blood will be used to perform independent validations. This study is designed as a correlation study to understand 1) how LFI assay results compare with results from traditional diagnostic methods based on DNA detection methods and bacterial culture isolate on bubo aspirate or sputum and 2) effectiveness of capillary blood to serve as a diagnostic clinical sample as compared with traditional biological samples (venous blood, bubo and sputum). The study is designed to evaluate the outcome of LFI and how LFI results correlate with the standard plague diagnostics methods used in Madagascar and other methods. We are not examining the relationship between the results of the LFI and health outcomes of the participants. Decision of participant's medical treatment is solely based on the clinical judgment of the physician and guidelines set forth by Madagascar National Plague Control Program (PNLP); no formal test is involved with medical decision. All participants who are tested by LFI will have received medical treatment prior to the start of the study and the continuation of their medical treatment is guided by PNLP and physician judgment only. Again, we are not looking at the relationship between the results of the LFI and health outcomes of the participants.

From the non-suspect cohort, greater detail will be provided as obtained. In brief, this subject population will consist of active duty US Naval personnel and DoD beneficiaries presenting to participating study sites in the United States with influenza-like symptoms (fever, cough, sore throat). Since the US is non-endemic for plague, all participants will be presumed to be negative for Y. pestis.

Eligibility criteria: Inclusion criteria - Malagasy Participants

1. Adults 18 to 75 years old (male and female): Able to receive and give verbal communication.
2. Children 5 to 17 years old (vulnerable population): Parents or legal guardian must be available to give permission. Parents or legal guardian to consent for children (5-6 years).
3. Suspected human plague case by local medical professional. Include at least one of the following: For bubonic plague: high fever, chills, and/or presence of painful bubo; For pneumonic plague: high fever, chills, cough for less than 5 days, bloody sputum, and/or chest pains; patients may be recruited from both plague surveillance program and non-plague surveillance programs.

Exclusion criteria - Malagasy Participants

1. Children under the age of 5 years old
2. Children between the age of 5 years to 17 years without a parent or legal guardian
3. Not compliant with the study procedure (blood sampling)

Inclusion criteria - USN Health Center Participants

1. Active duty personnel and DoD beneficiaries that present to participating study sites with influenza-like-illness (fever, cough, sore throat).
2. Age range \>=13 to 75 y.o.
3. Able to receive/give consent (or assent if \<18 y.o.) 4, Presenting with influenza-like-illness (fever of 100.5 F or higher, cough and/or sore throat)

5. USN Special Categories: Minors/children (45CFR Subpt. D/DoDI 3216.02, Encl 3, Para 7d); Students; Active duty military personnel (3216.02, Encl.3 Para. 7.e); Economically disadvantaged persons (32CFR 219.11(b); Educationally disadvantaged persons (32CFR 219.11(b).

Exclusion criteria - USN Health Center Participants

1. \<13 y.o.
2. Unable to give written consent (if under 18)

Primary outcomes:
measure: LFI results on finger-prick blood correlate with the results of standard WHO-approved diagnostic tests for plague
timeFrame: Up to 3 weeks post sample collection and processing of each participant.
Secondary outcomes:
measure: LFI results on finger-prick blood correlate with LFI results from bubo aspirate or sputum clinical matrices.
timeFrame: Up to 3 weeks post sample collection and processing of each participant.
Other outcomes:
measure: LFI results on finger-prick blood correlate with the test results on venous blood using the following diagnostic methods: LFI, qPCR, ELISA and FilmArray Warrior Panel.
timeFrame: Two years through sample collection and analysis completion from 05/2020 to 05/2022.
Locations:
city: San Diego
country: United States
facility: US Naval Health Research Center
state: California
city: Antananarivo
country: Madagascar
facility: Institut Pasteur de Madagascar
state: Analamanga
Study officials:
affiliation: Northern Arizona University
name: Dawn J Birdsell, Ph.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Northern Arizona University
name: David M Wagner, Ph.D.
role: STUDY_DIRECTOR
affiliation: Institut Pasteur de Madagascar
name: Minoarisoa Rajerison, Ph.D.
role: STUDY_DIRECTOR
affiliation: Institut Pasteur de Madagascar
name: Voahangy Andrianaivoarimanana, Ph.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Naval Health Research Center
name: Chris Myers, Ph.D.
role: STUDY_DIRECTOR
affiliation: Naval Health Research Center
name: Caroline Balagout
role: PRINCIPAL_INVESTIGATOR
affiliation: New Horizons Diagnostics, Inc./Brimrose Biotechnology, Corp.
name: David P Trudil
role: STUDY_CHAIR
References:
citation: Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Schoch-Spana M, Tonat K. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA. 2000 May 3;283(17):2281-90. doi: 10.1001/jama.283.17.2281.
citation: International meeting on preventing and controlling plague: the old calamity still has a future. Wkly Epidemiol Rec. 2006 Jul 14;81(28):278-84. No abstract available. English, French.
citation: Chanteau S, Rahalison L, Ralafiarisoa L, Foulon J, Ratsitorahina M, Ratsifasoamanana L, Carniel E, Nato F. Development and testing of a rapid diagnostic test for bubonic and pneumonic plague. Lancet. 2003 Jan 18;361(9353):211-6. doi: 10.1016/S0140-6736(03)12270-2.
citation: Stenseth NC, Atshabar BB, Begon M, Belmain SR, Bertherat E, Carniel E, Gage KL, Leirs H, Rahalison L. Plague: past, present, and future. PLoS Med. 2008 Jan 15;5(1):e3. doi: 10.1371/journal.pmed.0050003.
citation: Andrianaivoarimanana V, Kreppel K, Elissa N, Duplantier JM, Carniel E, Rajerison M, Jambou R. Understanding the persistence of plague foci in Madagascar. PLoS Negl Trop Dis. 2013 Nov 7;7(11):e2382. doi: 10.1371/journal.pntd.0002382. eCollection 2013 Nov.
citation: Rasoamanana B, Leroy F, Boisier P, Rasolomaharo M, Buchy P, Carniel E, Chanteau S. Field evaluation of an immunoglobulin G anti-F1 enzyme-linked immunosorbent assay for serodiagnosis of human plague in Madagascar. Clin Diagn Lab Immunol. 1997 Sep;4(5):587-91. doi: 10.1128/cdli.4.5.587-591.1997.